Wockhardt reported a 24% jump in Q2 FY2027 revenue to ₹969 crore, led by a 68% surge in its biotechnology segment. Despite this growth, net profit declined 11% to ₹73 crore amid rising costs. The company also secured a key regulatory victory as the DCGI lifted supply restrictions on its novel antibiotic, Miqnaf, clearing the path for wider market distribution in India.
Wockhardt Limited delivered a mixed performance for the second quarter of the fiscal year 2027, balancing strong revenue expansion with pressure on the bottom line. The company reported consolidated revenue of ₹969 crore, a 24% increase from ₹782 crore in the same period last year. This growth was primarily fueled by the company’s biotechnology division, which saw a 68% rise in revenue, reaching ₹252 crore.
While the top-line performance showed strength, profitability faced headwinds during the quarter. Net profit after tax dipped by 11% to ₹73 crore, compared to ₹82 crore in the second quarter of the previous fiscal year. This decline occurred even as the company saw higher demand, as total expenses for the quarter rose to ₹907 crore from ₹712 crore a year ago. Despite the quarterly dip, the company’s performance over the first half of the fiscal year shows a significant improvement, with a net profit of ₹180 crore compared to a net loss of ₹26 crore in the first half of fiscal year 2026.
Regulatory Milestone for Miqnaf
A significant highlight for the company is the regulatory update regarding its novel antibiotic, Miqnaf (nafithromycin). The Drugs Controller General of India (DCGI) has removed a supply condition that previously limited the drug's availability. With this restriction lifted, Wockhardt can now expand the distribution of Miqnaf across the Indian market. The company has indicated plans to deploy a dedicated sales force to support this rollout, citing strong clinical acceptance for the antibiotic's effectiveness against specific pathogens.
Looking ahead, Wockhardt is already preparing for the next phase of its antibiotic strategy. The firm is planning to file for an additional indication for Miqnaf—targeting upper respiratory tract infections—in the second half of the current fiscal year. This expansion is part of a broader push to solidify its position in the specialty care segment.
Operational Focus and Risks
The company’s global antibiotic strategy continues to center on Zaynich, its breakthrough drug that received US FDA approval in May 2026. While international operations and emerging markets like Brazil and Thailand have contributed to growth, investors should note that the pharmaceutical sector remains highly competitive. The company’s financial flexibility will depend on its ability to manage rising manufacturing and operational expenses while successfully commercializing its new product pipeline. Future performance will be closely tied to how efficiently the company can convert the regulatory approval for Miqnaf into sustained market share and how it manages overall cost structures in upcoming quarters.